Literature DB >> 26573701

Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.

Andrew G Hoss1, Valentina N Lagomarsino1, Samuel Frank1, Tiffany C Hadzi1, Richard H Myers1, Jeanne C Latourelle1.   

Abstract

BACKGROUND: Biomarkers for Huntington's disease progression could accelerate therapeutic developments and improve patient care. Brain microRNAs relating to clinical features of Huntington's disease may represent a potential Huntington's disease biomarker in blood.
OBJECTIVE: This study was undertaken to examine candidate microRNAs in plasma to determine whether changes observed in HD brains are detectable in peripheral samples.
METHODS: Four microRNAs from 26 manifest Huntington's disease, four asymptomatic Huntington's disease gene carriers, and eight controls were quantified in plasma using reverse transcription quantitative polymerase chain reaction. Linear regression was used to assess microRNA levels across control, asymptomatic gene carriers, and manifest patients.
RESULTS: miR-10b-5p (P = 0.0068) and miR-486-5p (P = 0.044) were elevated in Huntington's disease plasma. miR-10b-5p was decreased in asymptomatic gene carriers as compared with patients with Huntington's disease (P = 0.049), but no difference between asymptomatic gene carriers and healthy controls was observed (P = 0.24).
CONCLUSIONS: These findings suggest that microRNA changes observed in Huntington's disease brain may be detectable in plasma and have potential clinical utility.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; biomarker; blood; miRNA; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26573701      PMCID: PMC4715548          DOI: 10.1002/mds.26457

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  31 in total

1.  MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.

Authors:  Laura Poliseno; Min Sup Song; Su Jung Song; Ugo Ala; Kaitlyn Webster; Christopher Ng; Gary Beringer; Nicolai J Brikbak; Xin Yuan; Lewis C Cantley; Andrea L Richardson; Pier Paolo Pandolfi
Journal:  Cell       Date:  2013-07-03       Impact factor: 41.582

2.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Authors:  Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker
Journal:  Lancet Neurol       Date:  2014-11-03       Impact factor: 44.182

3.  Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

Authors:  F Borovecki; L Lovrecic; J Zhou; H Jeong; F Then; H D Rosas; S M Hersch; P Hogarth; B Bouzou; R V Jensen; D Krainc
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

4.  PET imaging shows loss of striatal PDE10A in patients with Huntington disease.

Authors:  Rawaha Ahmad; Sophie Bourgeois; Andrey Postnov; Mark E Schmidt; Guy Bormans; Koen Van Laere; Wim Vandenberghe
Journal:  Neurology       Date:  2013-12-18       Impact factor: 9.910

5.  A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.

Authors:  Aaron Sturrock; Corree Laule; Katy Wyper; Ruth A Milner; Joji Decolongon; Rachelle Dar Santos; Allison J Coleman; Kimberley Carter; Susan Creighton; Natalie Bechtel; Stefan Bohlen; Ralf Reilmann; Hans J Johnson; Michael R Hayden; Sarah J Tabrizi; Alex L Mackay; Blair R Leavitt
Journal:  Mov Disord       Date:  2015-02-18       Impact factor: 10.338

6.  Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease.

Authors:  Deborah L Harrington; Dawei Liu; Megan M Smith; James A Mills; Jeffrey D Long; Elizabeth H Aylward; Jane S Paulsen
Journal:  Brain Behav       Date:  2013-11-13       Impact factor: 2.708

7.  miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.

Authors:  Andrew G Hoss; Adam Labadorf; Jeanne C Latourelle; Vinay K Kartha; Tiffany C Hadzi; James F Gusella; Marcy E MacDonald; Jiang-Fan Chen; Schahram Akbarian; Zhiping Weng; Jean Paul Vonsattel; Richard H Myers
Journal:  BMC Med Genomics       Date:  2015-03-01       Impact factor: 3.063

8.  8OHdG is not a biomarker for Huntington disease state or progression.

Authors:  Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

9.  Plasma processing conditions substantially influence circulating microRNA biomarker levels.

Authors:  Heather H Cheng; Hye Son Yi; Yeonju Kim; Evan M Kroh; Jason W Chien; Keith D Eaton; Marc T Goodman; Jonathan F Tait; Muneesh Tewari; Colin C Pritchard
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

10.  MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.

Authors:  Andrew G Hoss; Vinay K Kartha; Xianjun Dong; Jeanne C Latourelle; Alexandra Dumitriu; Tiffany C Hadzi; Marcy E Macdonald; James F Gusella; Schahram Akbarian; Jiang-Fan Chen; Zhiping Weng; Richard H Myers
Journal:  PLoS Genet       Date:  2014-02-27       Impact factor: 5.917

View more
  11 in total

1.  Association of variants in microRNA with Parkinson's disease in Chinese Han population.

Authors:  Fang Li; Han Liu; Yuan Cheng; Jing Yang; Yutao Liu; Yanlin Wang; Zhihua Yang; Changhe Shi; Yuming Xu
Journal:  Neurol Sci       Date:  2017-12-05       Impact factor: 3.307

Review 2.  Epigenetic mechanisms of neurodegenerative diseases and acute brain injury.

Authors:  Mario J Bertogliat; Kahlilia C Morris-Blanco; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2019-12-12       Impact factor: 3.921

3.  Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7.

Authors:  Verónica M Borgonio-Cuadra; Claudia Valdez-Vargas; Sandra Romero-Córdoba; Alfredo Hidalgo-Miranda; Yessica Tapia-Guerrero; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Mol Neurobiol       Date:  2019-02-05       Impact factor: 5.590

Review 4.  miRNA-486-5p: signaling targets and role in non-malignant disease.

Authors:  Adrianna Douvris; Jose Viñas; Kevin D Burns
Journal:  Cell Mol Life Sci       Date:  2022-06-22       Impact factor: 9.207

Review 5.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

6.  MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.

Authors:  Eric R Reed; Jeanne C Latourelle; Jeremy H Bockholt; Joli Bregu; Justin Smock; Jane S Paulsen; Richard H Myers
Journal:  Neurology       Date:  2017-12-27       Impact factor: 11.800

Review 7.  Stress-induced changes in miRNA biogenesis and functioning.

Authors:  Marta Olejniczak; Anna Kotowska-Zimmer; Wlodzimierz Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2017-07-17       Impact factor: 9.261

8.  CDC42 expression is altered by dioxin exposure and mediated by multilevel regulations via AhR in human neuroblastoma cells.

Authors:  Tuan Xu; Heidi Q Xie; Yunping Li; Yingjie Xia; Yangsheng Chen; Li Xu; Lingyun Wang; Bin Zhao
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

Review 9.  Small RNAs, Big Diseases.

Authors:  Iwona Rzeszutek; Aditi Singh
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

Review 10.  Role of non-coding RNAs in non-aging-related neurological disorders.

Authors:  A S Vieira; D B Dogini; I Lopes-Cendes
Journal:  Braz J Med Biol Res       Date:  2018-06-11       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.